HRPK20030766B3 - Combination of a taxane and cyclin-dependent kinase inhibitor - Google Patents

Combination of a taxane and cyclin-dependent kinase inhibitor

Info

Publication number
HRPK20030766B3
HRPK20030766B3 HR20030766A HRP20030766A HRPK20030766B3 HR PK20030766 B3 HRPK20030766 B3 HR PK20030766B3 HR 20030766 A HR20030766 A HR 20030766A HR P20030766 A HRP20030766 A HR P20030766A HR PK20030766 B3 HRPK20030766 B3 HR PK20030766B3
Authority
HR
Croatia
Prior art keywords
cyclin
taxane
combination
dependent kinase
kinase inhibitor
Prior art date
Application number
HR20030766A
Other languages
English (en)
Croatian (hr)
Inventor
Bissery Marie-Christine
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20030766A2 publication Critical patent/HRP20030766A2/hr
Publication of HRPK20030766B3 publication Critical patent/HRPK20030766B3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20030766A 2001-03-23 2002-03-22 Combination of a taxane and cyclin-dependent kinase inhibitor HRPK20030766B3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (2)

Publication Number Publication Date
HRP20030766A2 HRP20030766A2 (en) 2005-06-30
HRPK20030766B3 true HRPK20030766B3 (en) 2006-11-30

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030766A HRPK20030766B3 (en) 2001-03-23 2002-03-22 Combination of a taxane and cyclin-dependent kinase inhibitor

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
JP4764165B2 (ja) * 2002-11-06 2011-08-31 サイクラセル リミテッド ドセタキセル及びｃｄｋ阻害剤を含む組合せ
EP1986632B1 (en) * 2006-02-10 2012-08-15 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
JP6080837B2 (ja) * 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
KR100879712B1 (ko) 2009-01-22
JP2004521140A (ja) 2004-07-15
CZ20032551A3 (en) 2004-07-14
YU69503A (sh) 2006-08-17
TWI355935B (en) 2012-01-11
PE20020907A1 (es) 2002-12-19
CA2441441C (en) 2009-05-26
DE60226710D1 (de) 2008-07-03
ZA200307381B (en) 2005-03-30
NO20034124D0 (no) 2003-09-16
NO20034124L (no) 2003-09-16
CN1498107A (zh) 2004-05-19
EP1372652A2 (en) 2004-01-02
MEP16408A (en) 2010-10-10
PL367702A1 (en) 2005-03-07
SK11692003A3 (sk) 2004-03-02
BR0208221A (pt) 2004-03-02
NZ527655A (en) 2006-03-31
AR034222A1 (es) 2004-02-04
SK287481B6 (sk) 2010-11-08
HUP0303589A2 (hu) 2004-03-01
IL158058A (en) 2010-02-17
ATE395917T1 (de) 2008-06-15
WO2002076484A2 (en) 2002-10-03
MXPA03007743A (es) 2004-11-12
CZ301423B6 (cs) 2010-02-24
CA2441441A1 (en) 2002-10-03
HRP20030766A2 (en) 2005-06-30
IL158058A0 (en) 2004-03-28
AU2002312815B2 (en) 2006-08-24
US20020182204A1 (en) 2002-12-05
UY27220A1 (es) 2002-09-30
WO2002076484A3 (en) 2003-01-03
EA007815B1 (ru) 2007-02-27
EA200301053A1 (ru) 2004-02-26
RS50681B (sr) 2010-06-30
HUP0303589A3 (en) 2007-05-02
CY1110449T1 (el) 2015-04-29
ES2305253T3 (es) 2008-11-01
SI1372652T1 (sl) 2008-10-31
EP1372652B1 (en) 2008-05-21
US20060128640A1 (en) 2006-06-15
PL206118B1 (pl) 2010-07-30
DK1372652T3 (da) 2008-09-22
NO332441B1 (no) 2012-09-17
KR20030086318A (ko) 2003-11-07
HU229258B1 (en) 2013-10-28
PT1372652E (pt) 2008-07-24

Similar Documents

Publication Publication Date Title
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
BR0212921A (pt) Composição farmacêutica com base em fondant
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
SE0102315D0 (sv) Compounds
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
HUP0400723A3 (en) Isoxazoline derivatives and herbicide composition comprising the same as active ingredient
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
BRPI0410555A (pt) preparação sólida
HN2002000300A (es) Nuevos derivados de piperazina
ATE357228T1 (de) Feste pharmazeutische formulierung enthaltend modafinil
SE0101932D0 (sv) Pharmaceutical combinations
IT1320080B1 (it) Composizione per uso farmaceutico o dietetico.
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
WO2005065639A3 (en) Novel pharmaceutical compositions
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
ITMI20001093A0 (it) Composizioni a rilascio controllato contenenti un principio attivo, preferibilmente melatonina, e processo di preparazione delle stesse.
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
CR7198A (es) Tableta que contiene cetirizina y pseudoefedrina
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
NO20034524L (no) 5-leddete heterocykler, fremstilling og anvendelse derav som MAO inhibitorer og lipidperoksidasjonsinhibitorer, fremstilling derav oganvendelse derav sommedikamenter

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120229

Year of fee payment: 11

PK10 Patent expired after termination of 10 years for consensual patent

Effective date: 20120323